The multidisciplinary team of pediatric oncology investigators at the Medical College of Virginia win: (1) participate collaboratively with the Pediatric Oncology Group in cooperative research programs to determine the optimal treatment regimens for infants, children and adolescents with leukemia and solid tumors; (2) continue to provide leadership in the treatment of childhood rhabdomyosarcoma through the Intergroup Rhabdomyosarcoma Study of POG and CCSG; (3) provide leadership in studies of non-rhabdomyosarcoma soft tissue sarcomas, leukemia studies, and bone marrow transplantation; (4) develop and participate in POG pilot studies in childhood cancer; (5) continue an active role in POG administrative activities; (6) collect precise data by highquality performance and adherence to protocol procedures and record-keeping; and (7) participate in modality and disease-oriented subcommittees of POG to develop multidisciplinary studies of therapy for childhood cancer.
|Parham, D M; Webber, B L; Jenkins 3rd, J J et al. (1995) Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol 8:705-10|
|McWilliams, N B; Hayes, F A; Green, A A et al. (1995) Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study. Med Pediatr Oncol 24:176-80|
|Massey, G V; McCrady, C W; Dunn, N L et al. (1989) Induction of tumoricidal activity and alterations of growth by interleukin-2 and manipulation of protein kinase C and cytosolic calcium in childhood acute lymphocytic leukemia cells. Leukemia 3:602-10|